Efficacy of 10-day decitabine in acute myeloid leukemia.
Acute myeloid leukemia
Decitabine
Real world outcomes
Treatment
Journal
Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
01
12
2020
revised:
01
02
2021
accepted:
03
02
2021
pubmed:
1
3
2021
medline:
23
6
2021
entrez:
28
2
2021
Statut:
ppublish
Résumé
The azanucleotide decitabine is used in the treatment of acute myeloid leukemia (AML). Studies have shown conflicting results with 10-day regimens used in previously untreated AML patients. Additionally, there is little data on 10-day decitabine regimens in the relapsed setting. This study investigated outcomes of 108 adult patients with AML in the upfront and relapsed setting treated with a 10-day decitabine regimen. In the upfront group, the overall response rate (ORR, CR + CRi) was 36.1% and the median overall survival (OS) was 6.6 months, while the relapsed/refractory group had an ORR of 25% with an OS of 4.8 months. When analyzed with respect to cytogenetics, the upfront group featured an ORR of 28.1% with an OS of 9.4 months in the intermediate cytogenetic cohort compared to a 40.5% ORR and an OS of 5.4 months in the unfavorable cytogenetic cohort. An analysis of the relapsed/refractory group demonstrated an ORR of 26.3% with an OS of 7.9 months for intermediate cytogenetics versus 25.0% with an OS of 1.8 months in the unfavorable cohort. While these response rates are similar to previously published data, the median OS appears shorter.
Identifiants
pubmed: 33640708
pii: S0145-2126(21)00025-4
doi: 10.1016/j.leukres.2021.106524
pmc: PMC9006187
mid: NIHMS1677916
pii:
doi:
Substances chimiques
Decitabine
776B62CQ27
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106524Subventions
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197991
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Blood. 2017 Dec 7;130(23):2469-2474
pubmed: 29051180
Cancer Med. 2017 Dec;6(12):2814-2821
pubmed: 29058375
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8
pubmed: 20368434
Hematology Am Soc Hematol Educ Program. 2005;:137-42
pubmed: 16304371
Blood. 2015 Jul 16;126(3):319-27
pubmed: 25852056
Lancet Haematol. 2019 Apr;6(4):e177
pubmed: 30926076
Blood. 2009 Jul 30;114(5):937-51
pubmed: 19357394
Leuk Lymphoma. 2014 Jul;55(7):1533-7
pubmed: 24144313
Future Oncol. 2019 Jun;15(17):1989-1995
pubmed: 31170814
Lancet Haematol. 2019 Apr;6(4):e178
pubmed: 30926077
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Leukemia. 2009 Jun;23(6):1131-8
pubmed: 19194465
J Clin Oncol. 2004 Aug 15;22(16):3432-3
pubmed: 15310791
N Engl J Med. 2016 Nov 24;375(21):2023-2036
pubmed: 27959731
Blood. 2012 Dec 6;120(24):4840-5
pubmed: 23071272
Lancet Haematol. 2019 Jan;6(1):e29-e37
pubmed: 30545576
Blood Adv. 2018 Dec 26;2(24):3608-3617
pubmed: 30567725
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Ther Adv Hematol. 2019 Jan 11;10:2040620718816698
pubmed: 30719265
Leuk Lymphoma. 2017 May;58(5):1022-1036
pubmed: 27654579
Leuk Lymphoma. 2013 Sep;54(9):2003-7
pubmed: 23270581
Genes Cancer. 2012 Jan;3(1):71-81
pubmed: 22893792
Oncogene. 2002 Aug 12;21(35):5483-95
pubmed: 12154409
Blood. 2004 Mar 1;103(5):1635-40
pubmed: 14604977
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Am J Hematol. 2015 Jul;90(7):639-46
pubmed: 25808347
Leuk Res. 2020 Mar;90:106314
pubmed: 32035355
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
J Clin Oncol. 2012 Jul 20;30(21):2670-7
pubmed: 22689805
Ann Hematol. 2020 Mar;99(3):501-511
pubmed: 31965269
Adv Exp Med Biol. 2018;995:97-116
pubmed: 30539507
PLoS One. 2010 Feb 02;5(2):e9001
pubmed: 20126405
J Cell Physiol. 2019 Aug;234(8):14040-14049
pubmed: 30623427
Oncotarget. 2017 Jun 20;8(25):41498-41507
pubmed: 28489568